BioSphere, DuPont in vascular research pact:
This article was originally published in Clinica
Executive Summary
Bioengineered microsphere manufacturer BioSphere Medical and DuPont Applied BioSciences have teamed to evaluate potential peripheral vascular and embolotherapy research, development and manufacturing projects. The non-binding deal sees the two companies combine BioSphere's capability in developing and marketing minimally-invasive endovascular products with DuPont's focus on transformative medical devices. Additionally, Rockland, Massachusetts-based BioSphere and DuPont, a subsidiary of Wilmington, Delaware-based sciences giant DuPont, have also agreed to collaborate in a manufacturing yield improvement project agreement. This collaboration is aimed at improving the manufacturing yield of BioSphere's Embosphere and EmboGold microspheres with the help of DuPont's know-how. This deal will see BioSphere make payments to DuPont of up to $500,000 upon the achievement of certain milestones. Both companies will share the cost savings that result from the yield improvement plan, however, BioSphere will have the right to credit any of its milestone payments against its cost-saving obligations.